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Abstract 
Purinergic signalling appears to play important roles in neurodegeneration, neuroprotection and 
neuroregeneration. Initially there is a brief summary of the background of purinergic signalling, 
including release of purines and pyrimidines from neural and non-neural cells and their 
ectoenzymatic degradation, and the current characterisation of P1 (adenosine), and P2X (ion 
channel) and P2Y (G protein-coupled) nucleotide receptor subtypes. There is also coverage of 
the localization and roles of purinoceptors in the healthy central nervous system. The focus is 
then on the roles of purinergic signalling in trauma, ischaemia, stroke and in neurodegenerative 
diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases, as well as multiple 
sclerosis and amyotrophic lateral sclerosis. Neuroprotective mechanisms involving purinergic 
signalling are considered and its involvement in neuroregeneration, including the role of adult 
neural stem/progenitor cells. 
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Abbreviations: Aβ, β-amyloid; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; 
APP, amyloid precursor protein; EAE, experimental autoimmune encephalomyelitis; GABA, γ-
3 
 
amino butyric acid; BzATP, 2'- and 3'-O-(4-benzoylbenzoyl)-ATP; BBG, Brilliant Blue G; 
AP4A, diadenosine tetraphosphate; ERK, extracellular signal-regulated protein kinase; HD, 
Huntington’s disease; IL, interleukin; KO, knockout; NO, nitric oxide; MS, multiple sclerosis; 
NMDA, N-methyl-D-aspartate; 6-OHDA, 6-hydroxydopamine; OPs, oligodendrocyte progenitor 
cells; PD, Parkinson’s disease; PK, protein kinase; PPADS, pyridoxalphosphate-6-azophenyl-
2',4'-disulfonic acid; SOD1, superoxide dismutase 1; Treg, regulatory T cells; TNFα, tumour 
necrosis factor-α; WT, wild type. 
 
1. Introduction  
Purinergic signalling, adenosine 5’-triphosphate (ATP) acting as an extracellular signalling 
molecule, was proposed in 1972 (Burnstock, 1972). In 1976 the concept was introduced that 
ATP is a cotransmitter in most if not all nerves in the peripheral and central nervous system 
(CNS) (Burnstock, 1976; see Burnstock, 2014). Two families of receptors for purines were 
recognised in 1978, P1 receptors for adenosine and P2 receptors for ATP and adenosine 5’-
diphosphate (ADP) (Burnstock, 1978). In the early 1990s, receptors for purines and pyrimidines 
were cloned and characterised (see Ralevic and Burnstock, 1998). Currently it is established that 
there are four subtypes of the adenosine P1 receptor (A1, A2A, A2B, A3), seven subtypes of the 
P2X ion channel receptor (P2X1-7) and eight subtypes of P2Y G protein-coupled receptor 
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14) (see Burnstock, 2007a). Ectoenzymes 
that hydrolyse ATP and adenosine released from cells have been identified (see Zimmermann, 
2000; Yegutkin, 2014) and release of purines and pyrimidines from nerves and most non-
neuronal cell types in response to mechanical stimulation described (see Burnstock, 1999; 
Lazarowski et al., 2011).  
The actions of adenosine in the CNS were recognised early (see Phillis and Wu, 1981; 
Williams, 1984; Dunwiddie, 1985; Snyder, 1985), while consideration of the role(s) of ATP in 
the CNS received more attention later (see Bo and Burnstock, 1994; Burnstock, 1996, 2003, 
2007b; Gibb and Halliday, 1996; Inoue et al., 1996; Abbracchio, 1997; Illes and Zimmermann, 
1999; Masino and Dunwiddie, 2001; North and Verkhratsky, 2006). In particular, fast purinergic 
synaptic transmission has been clearly identified in the brain (Edwards et al., 1992; Bardoni et 
al., 1997; Nieber et al., 1997; Pankratov et al., 1999, 2002, 2009; Khakh, 2001; Mori et al., 2001; 
Robertson et al., 2001). Adenosine is the predominant, presynaptic modulator of transmitter 
release in the CNS (see Dunwiddie, 1985). However, ATP can also act presynaptically (Cunha 
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and Ribeiro, 2000). Local network behaviours are regulated by the balance between the effects of 
ATP, adenosine and ectonucleotidases on synaptic transmission (Kato et al., 2004; Matsuoka and 
Ohkubo, 2004). Adenosine is produced by ectoenzymatic breakdown of released ATP, but 
subpopulations of brain neurons and/or astrocytes have been claimed to release adenosine 
directly (Wall and Dale, 2007). 
 There are high concentrations of ATP within the brain, about 2 mmol/kg in the cortex to 
4 mmol/kg in the putamen and hippocampus (Kogure and Alonso, 1978). Cortex and 
hippocampus synaptic membranes exhibit higher activities of NTPDase1 and NTPDase2 than 
cerebellum and medulla oblongata. Ecto-5'-nucleotidase and adenosine deaminase are found in 
most brain regions (Kukulski et al., 2004). There is heterogeneous distribution in the CNS of 
both P2X receptors (Llewellyn-Smith and Burnstock, 1998; Loesch and Burnstock, 1998; 
Kanjhan et al., 1999; Burnstock and Knight, 2004; Guo et al., 2008) and P2Y receptors (Moore 
et al., 2000; Morán-Jiménez and Matute, 2000; Burnstock, 2003; Miras-Portugal et al., 2007). A 
recent review discussed the roles of P2X receptors in the CNS in health and disease (Burnstock, 
2015). P2X2, P2X4 and P2X6 receptors often form heteromultimers. P2X1 receptors are 
expressed in some regions of the brain, such as cerebellum, while P2X3 receptors are expressed 
in the brain stem. P2X7 receptors are probably largely presynaptic. The dominant adenosine 
receptor subtype in the brain is A1, but A2B and A3 receptors have also been identified in some 
regions of the brain (Latini and Pedata, 2001). Nucleotides can act synergistically with growth 
factors to regulate trophic events (Neary et al., 1994; Rathbone et al., 1999; Burnstock and 
Verkhratsky, 2010). Some brain stem neurons appear to control autonomic functions via 
purinoceptors (see Burnstock, 2007b). 
 There is compelling evidence for the role of ATP as a cotransmitter with classical 
transmitters in the CNS. ATP is coreleased with acetylcholine from cortical synaptosomes and 
for a smaller number ATP is coreleased with noradrenaline (Potter and White, 1980). There is 
corelease of ATP with catecholamines from neurons in the locus coeruleus (Poelchen et al., 
2001) and hypothalamus (Buller et al., 1996; Sperlágh et al., 1998). Corelease of ATP with γ-
amino butyric acid (GABA) occurs in dorsal horn and lateral hypothalamic neurons (Jo and 
Role, 2002). Corelease of ATP with glutamate in the hippocampus (Mori et al., 2001) and with 
dopamine in the CNS (Krügel et al., 2003) has also been reported.  
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Multiple P1 and P2 receptor subtypes are expressed by astrocytes, oligodendrocytes and 
microglia (see Burnstock and Knight, 2004; Verkhratsky et al., 2009). ATP mediates both short-
term calcium signalling events and long-term proliferation, differentiation and death of glia 
(Cotrina et al., 2000). Purinergic receptors have also been identified on adult neural stem cells 
(Mishra et al., 2006; Ulrich et al., 2012). Purinergic signalling is a major means of integrating 
functional activity between neurons, glial and vascular cells in the CNS (see Abbracchio and 
Burnstock, 1998; Fields and Burnstock, 2006; Parpura and Zorec, 2010; Matute and Cavaliere, 
2011; Verderio and Matteoli, 2011).  
 A discussion of the involvement of purinergic signalling in neurodegeneration, 
neuroprotection and regeneration has been included in a number of reviews (Franke and Illes, 
2006; Burnstock, 2007b, 2015; Abbracchio et al., 2009; Burnstock and Verkhratsky, 2012; Illes 
et al., 2012; Ulrich et al., 2012; Volonté and Burnstock, 2012). It is clear that the involvement of 
purinergic signalling is complex and involves the combined activity resulting from ATP release, 
receptor activation and ectonucleotide enzyme activity. 
 The involvement of ATP in peripheral (including enteric) nerve degeneration and 
regeneration has also been studied (see Tokui et al., 1994; Schäfer et al., 1995; Xu et al., 2013; 
Jung et al., 2014), but will not be covered in this review article, which is focussed on the CNS. 
 
2. Trauma, ischaemia and stroke 
Trauma, ischaemia and stroke lead to the release of ATP/adenosine from cells in the CNS (Neary 
et al., 1996; Abbracchio and Burnstock, 1998). These signalling molecules play two roles: partly 
to aggravate the neuronal and glial damage caused by mechanical trauma/metabolic limitation, 
and partly to serve as protective mechanisms (see Zimmermann, 1994; Fields and Stevens-
Graham, 2002; Neary et al., 2003; Même et al., 2004; Franke et al., 2006a ; Majumder et al., 
2007). Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), a P2 receptor antagonist, 
supports recovery from experimental stroke in vivo (Lämmer et al., 2011).  
 ATP release appears to be important in triggering cellular responses to trauma (see 
Franke et al., 2006a). Astrocytes sense the severity of damage in the CNS via ATP release from 
damaged cells and they can modulate the tumour necrosis factor-α (TNF-α)-mediated 
inflammatory response. Micromolar ATP activation of P2Y receptors boosts a moderate 
inflammatory response, while millimolar ATP activation of P2X receptors appears to prevent the 
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perpetuation of a comparatively large inflammatory response. Astrocytic release of ATP has 
been demonstrated in vivo to be essential in mediating the injury-induced defensive responses of 
microglial processes (Davalos et al., 2005). Upon traumatic brain injury, microglial processes 
rapidly converge on the site of injury without cell body movement. This chemotactic response 
can be mimicked by local injection of ATP and can be inhibited by blockers of P2Y receptors. 
Microglial cells orchestrate inflammatory brain responses to trauma and hypoxia. They are 
activated by purines and pyrimidines to release the inflammatory cytokines interleukin (IL)-1β 
and IL-6 and TNF-α. Resting microglia, characterised by a complex network of processes, 
migrate to the site of damage after brain trauma, where they are transformed into the activated 
amoeboid form; ATP has been shown to replicate this transformation (Xiang et al., 2006). 
 Cerebellar lesions produce up-regulation of P2X1 and P2X2 receptors in precerebellar 
nuclei (Florenzano et al., 2002). Stab wound injury in the nucleus accumbens led to increase in 
expression of subtypes of P2X and P2Y receptors (Franke et al., 2006a). A significant increase in 
ecto-NTPDase and ecto-5’nucleotidase activities occurs following cortical stab injury in rats, 
whereas in other brain areas only as increase in 5’-nucleotidase activity was seen (Nederljkovic 
et al., 2006). After stab wound injury, previously absent P2X1 and P2X7 receptor-
immunoreactivity was observed on cells labelled for the astrocytic marker glial fibrillary acidic 
protein (Franke et al., 2001). Cortical stab injury induced rapid focal varicose swelling that 
developed into beading of NTPDase 3-positive fibres expressing P2X2 receptors (Bjelobaba et 
al., 2010). Changes in expression of ecto-5'-nucleotidase have been described in the rat model of 
cortical stab injury (Bjelobaba et al., 2011). P2Y1, P2Y2 and P2Y6 receptor-immunoreactivity 
also became apparent on astrocytes around the stab wound (Franke et al., 2004b). Reduction of 
long-term neurologic injury after blunt spinal trauma is evoked by A2A receptor agonists (Reece 
et al., 2004). ATP and nitric oxide (NO) play key roles in mediating neuronal responses after cell 
damage. Nitrergic and purinergic systems are activated after cerebellar lesion. Colocalisation of 
P2X1 and P2X2 receptors with neuronal NO synthase was observed in olivary and pontine 
neurons (Viscomi et al., 2004).The inhibitory effects of ATP on NO production correlates with 
activation of the transcription factor cyclic AMP response element-binding protein (Brautigam et 
al., 2005). After nerve injury P2X4 receptors induced in spinal microglia gate tactile allodynia 
(Tsuda et al., 2003). 
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P2X7 receptors are activated by ATP released during trauma and inflammation (Le 
Feuvre et al., 2002). Signalling via P2X7 receptors may allow cells to sense and respond to 
events occurring in the extracellular environment, modulate the genes involved in inflammatory 
responses and regulate cytokine responses in the CNS. P2X7 receptors play a role in mediating 
spinal cord injury (Wang et al., 2004). Since P2X7 receptors are highly expressed in spinal cord 
neurons, it was concluded that spinal cord injury is associated with prolonged activation of these 
receptors, which results in excitotoxicity-based neuronal degeneration. This study supports the 
role of ATP as an early danger signal in neurodegenerative damage. ATP-induced stimulation of 
P2X7 receptors releases not only ATP and glutamate, but also GABA from astrocytes of the 
brain (Wang et al., 2002). Thus the hypoxic release of ATP may exert both excitatory and 
inhibitory neuronal modulation via glutamate and GABA, respectively (Wirkner et al., 2005).  
Receptor-positive neurons and glial cells in the rat nucleus accumbens showed significant 
increase in the number of P2Y1 after injury and coexpression of P2Y1 receptors and vesicular 
glutamate transporter immunopositive cells was observed (Franke et al., 2006b). The authors 
concluded that the enhanced sensitivity of neurons to purinergic signalling in trauma may be 
related to changes in glutamatergic transmission. Focal cerebral ischaemia induced by 
intraluminal occlusion of the right middle cerebral artery results in the release of ATP into the rat 
striatal microdialysate (Melani et al., 2005). Mechanical injury to the rat nucleus accumbens 
elevated the concentrations of both ATP and glutamate in the microdialysate (Franke et al., 
2006b). The local increase in the ATP concentration may lead to the up-regulation of the ecto-
nucleotidases hydrolyzing extracellular ATP (Braun et al., 1998). ATP together with glutamate 
may exert an excitotoxic action, thereby causing the death of previously uninjured neurons and 
astrocytes (Dallas et al., 2007). The hypoxia-induced outflow of glutamate may be the 
consequence of the release of ATP (Rodrigues et al., 2005; Zhang et al., 2006; Sperlágh et al., 
2007).  
 Mechanical injury to the rat spinal cord caused an immediate, irreversible loss of tissue 
at the lesion site, as well as secondary extensive tissue damage over time (Wang et al., 2004; 
Peng et al., 2009). The secondary tissue damage was partially due to the release of ATP and its 
mediation by P2X7 receptors.  
 P2X7 receptors appear to be the main triggers of necrosis/apoptosis in mechanically or 
ischaemically damaged CNS cells, but other P2X receptor subtypes are probably also involved 
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(Franke and Illes, 2006; Volonté et al., 2003). Unilateral cerebellectomy axotomized 
precerebellar neurons, for example, either degenerated, or became immunopositive for P2X1 and 
P2X2 receptors (Florenzano et al., 2002). Also P2Y1, P2X3 as well as P2X7 receptors played a 
detrimental role in neurotransmission in CA1 hippocampus during oxygen and glucose 
deprivation, causing downstream activation of extracellular signal-regulated protein kinase 
(ERK)1/2 that is involved in cell excitability and death (Traini et al., 2011). P2 receptor 
antagonists prevented the synaptic failure. 
 In cultured oligodendrocytes, in contrast to astrocytes and neurons, hypoxia/ischaemia 
down-regulates P2X7 expression (Wang et al., 2009). In healthy animals, P2X7 receptor-
immunoreactivity was absent from microglia, but appeared after middle cerebral artery 
occlusion. The P2 receptor antagonist, reactive blue 2, reduced the ischaemic damage. Further, a 
P2Y receptor on microglia directed the convergence of these cells to the site of traumatic injury, 
establishing a barrier between the healthy and injured tissue (Davalos et al., 2005). The 
expression of P2X7 receptors, accompanying the activation of brain microglia after mechanical 
injury, is an early reaction, followed later by the appearance of these receptors on glial cells and 
probably also neurons (Franke et al., 2007).  
 There are changes in the second messenger mechanisms coupled to P2X and P2Y 
receptors activated by nucleotides following brain damage. For P2X receptors, a rapid increase 
of intracellular Ca2+ and activation of Ca2+-dependent enzymatic pathways is the primary 
mediator of early and long-term cellular changes. P2Y receptor subtypes are linked to the protein 
kinase signalling pathways regulating cellular proliferation, differentiation and survival such as 
ERK and PKB/Akt (Neary and Kang, 2005; Neary and Zimmermann, 2009). After trauma, P2 
receptor/protein kinase cascades are activated, induced by mechanical and ischaemic stress, 
leading to late responses of glial cells, including proliferation (glial scars) of astroglia and 
demyelination in the white matter of oligodendroglia.  
 Protein kinase (PK) B/Akt is a signalling molecule that regulates cell survival, growth 
and metabolism and inhibits apoptosis. Traumatic brain injury activates Akt. ATP was released 
when cortical astrocytes were subjected to mechanical strain, leading to Akt activation and 
PPADS attenuated the Akt activation (Neary et al., 2005). Mechanical strains comparable to 
those that occur in humans subjected to traumatic brain injury, cause release of ATP from 
astrocytes. Then there is activation of purinergic receptors coupled to protein kinase cascades 
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that regulate expression of genes involved in long-term, trophic actions (Neary et al., 2006). The 
activity of GSK-3, which is known to be involved in cell proliferation and survival, is regulated 
by ATP in astrocytes and is likely to be involved in the response of the brain to injury on release 
of ATP (Neary and Kang, 2006). 
 The significance of the hypoxia-induced release of ATP in the ventral medulla 
oblongata for respiratory control has been discussed (Rong et al., 2003; Gourine et al., 2005, 
2010). There is evidence to support the view that adenosine regulation is a significant factor in 
the onset and recovery of traumatic brain injury and therapeutic strategies based on P1 receptor 
compounds are being explored (Lusardi, 2009). Hypoxic-ischaemic injury to perinatal brain is a 
major contributor to morbidity in children and adenosine has been claimed to play a role in its 
pathophysiology (Pimental et al., 2015). The authors highlighted the potential role played by 
adenosine deaminase inhibitors to increase adenosine at the sites of injury. 
 Inflammation and immunity are major elements in the pathobiology of stroke. ATP 
released during ischaemic damage activated P2X7 receptors on microglia leading to release of 
proinflammatory cytokines and activated microglia migrate and exhibit macrophage-like activity 
via P2Y6 receptors (see Iadecola and Anrather, 2011; Figure 1). Recent reviews that discuss 
purinergic signalling and inflammation are available (Eltzschig et al., 2012; Fiebich et al., 2014; 
Idzko et al., 2014; Morandini et al., 2014). Ischaemic pathologies of white matter include a high 
proportion of stroke lesions (Fern et al., 2014).  
 
3. Neurodegenerative diseases 
Neurodegeneration is the basis of the wide range of neurodegenerative diseases, involving both 
neurons and glial cells and there is increasing evidence for the participation of purinergic 
signalling (see Burnstock, 2008; Burnstock and Verkhratsky, 2012). Microglia play an important 
role against infection in the CNS, but overstimulation of this immune reaction may accelerate the 
neuronal damage caused by neurodegenerative diseases and human immunodeficiency virus 
encephalopathy, which exhibit microglial proliferation and activation (Ogata et al., 2003). ATP 
inhibits cytokine release from lipopolysaccharide-activated microglia via P2Y receptors and it 
was suggested that P2Y agonists may be a potential treatment for toxic immunoreactions.  
 
3.1. Alzheimer's disease (AD) 
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There is evidence for the involvement of both P1 and P2 receptors in AD. ATP release during 
neuronal excitation or injury enhances the inflammatory effects of cytokines and prostaglandin 
E2 in astrocytes and contributes to the chronic inflammation seen in AD (Xu et al., 2003). 
Human brain tissue from patients who died with a confirmed diagnosis of AD consistently 
showed a loss of A1 receptors, especially most clearly in the outer layers of dentate gyrus in 
hippocampus, the region of the brain most intimately involved in the processes of learning and 
memory (Jansen et al. 1990; Ulas et al. 1993). The levels of A1 and A2A receptors, however, 
increased in the frontal cortex, in parallel with an increased function of these receptors (Albasanz 
et al. 2008). In AD, a key role is played by abnormal metabolism of the amyloid precursor 
protein (APP), which is cleaved by β- and γ-secretases to generate the β-amyloid (Aβ) peptides, 
present in large amounts in the amyloid plaques of AD patients’ brains. In post-mortem 
neocortical and hippocampal tissue from patients with AD, colocalization of A1 receptors with 
Aβ in senile plaques was reported (Angulo et al., 2003). It was shown that, in human 
neuroblastoma cells, activation of A1 receptors activated PKC, p21 Ras and ERK1/2, leading to 
increased formation of soluble Aβ fragments. These findings would implicate A1 receptors in Aβ 
metabolism and suggest that agonists at these receptors might be useful drugs for the treatment 
of established or late-stage AD (see Stone et al., 2009). 
There is evidence implicating P2 receptors, in particular P2X7, in AD. In an early study, 
primary rat microglia stimulated with either ATP or 2'- and 3'-O-(4-benzoylbenzoyl)-ATP 
(BzATP) were shown to release copious amounts of superoxide primarily via the increased 
expression of P2X7 receptors (Parvathenani et al., 2003). ATP and BzATP also stimulated 
microglia-induced cortical cell death suggesting that this pathway contributes to 
neurodegeneration. P2X7 receptors were shown to be up-regulated around Aβ plaques in a 
mouse model of AD (Tg2576) (Parvathenani et al., 2003). Enhanced expression of P2X7 
receptors in brain samples from six AD patients was reported (McLarnon et al., 2006).  
Prominent P2X7 receptor expression was observed in association with Aβ plaques on microglia. 
Cultured foetal human microglia cells exposed to amyloidogenic Aβ1-42 peptide had significantly 
elevated levels of P2X7 receptors compared with untreated cells. Aβ triggers increases in 
intracellular Ca2+ concentrations, ATP release, IL-1β secretion and plasma membrane 
permeabilization in microglia from wild type (WT) but not from P2X7 knockout (KO) mice 
(Sanz et al., 2009). Similarly, intra-hippocampal injection of Aβ caused a large accumulation of 
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IL-1 in WT but not in P2X7 KO mice. This suggests that Aβ activates a purinergic 
autocrine/paracrine stimulatory loop involving P2X7 receptors. In the APPswe/PS1dE9 mouse 
model of AD, P2X7 immunoreactivity was predominantly found in activated microglia before 
Aβ plaque formation, suggesting a causative role in disease onset. Further, during disease 
development, upregulation of P2X7 and reactive oxygen species production in microglia 
paralleled Aβ increase and was associated with synaptotoxicity (Lee et al., 2011). Thus, P2X7 
receptors mediate microglial purinergic inflammatory responses in AD brain. ATP reduces A 
protein misfolding in vitro (Coskuner and Murray, 2014). Activation of P2X7 receptor-
stimulated release of sAPPα from mouse and human neuroblastoma cells and from mouse 
primary astrocytes and neural progenitor cells was inhibited by P2X7 antagonists or by P2X7 
receptor knockdown with siRNAs. This was not observed in neural cells from P2X7 KO mice. 
Other P2X receptor subtypes have been implicated in AD. Aβ1-42 promoted accumulation of 
P2X4 receptors in neurons and induced caspase-3-mediated cleavage of the receptor that slowed 
channel closure times and prevented agonist-induced receptor internalization (Varma et al., 
2009). Reduced expression of P2X4 receptors in primary rodent neurons attenuated Aβ1-42-
induced neuronal death. In contrast, induced P2X4 expression in a neuronal cell line that does 
not normally express P2 receptors enhanced the toxic effect of Aβ1-42.  
In AD brains, P2Y1 receptors were localized to neurofibrillary tangles, neuritic plaques 
and neuropil threads (Moore et al., 2000). Activation of the P2Y2 receptor expressed in human 
1321N1 astrocytoma cells enhanced the release of sAPPα in a time- and dose-dependent manner 
(Camden et al., 2005). P2Y2 receptor-activated sAPPα release was partially suppressed by 
ADAM10 or ADAM17/TACE, while treatment of cells with both ADAM10 and 
ADAM17/TACE siRNA completely abolished uridine 5’-triphosphate-activated sAPPα release. 
APP expression and release from astrocytes are regulated by nucleotides through activation of 
P2Y2/4 receptors (Tran, 2011). The ATP synthase β subunit was identified as a new autoantigen 
in AD (Vacirca et al., 2010, 2011). A recent review presents evidence that there is a prominent 
role for P2Y receptors in AD pathology, including Aβ production and elimination, 
neuroinflammation, neuronal function and cerebral blood flow (Erb et al., 2015). Serum anti-
ATP synthase autoantibodies were observed in 38% of patients with AD, but not in healthy 
subjects or in patients with Parkinson's disease (PD) or atherosclerosis. ATP synthase 
autoantibodies have been proposed as potential serum biomarkers for AD. 
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3.2. Parkinson's disease (PD) 
The motor symptoms of PD are due to the degeneration of the dopaminergic neurons in 
the nigrostriatal pathway. A2A receptors have been implicated in the pathophysiology of PD, due 
to its extensive interaction with the dopaminergic system in extrapyramidal areas (Morelli et al., 
2010). An early event in PD is increased striatal A2A receptor expression (Villar-Menéndez et al., 
2014) and A2A receptor antagonists are being explored for the treatment of PD (Antonini and 
Poewe, 2014; Gyoneva et al., 2014; Perez-Lloret and Merello, 2014; Zheng et al., 2014). Readers 
are referred to a number of authoritative reviews about the role of A2A receptors in PD (Azam et 
al., 2009; Pinna, 2009; Jenner et al., 2009; Ciruela et al., 2011; Burnstock and Verkhratsky, 
2012) that also draw our attention to the possible involvement of other purinergic receptors. 
Data has implicated the P2X7 receptor in PD (Jun and Kin, 2004; Marcellino et al., 
2010). Nigral P2X7 immunoreactivity was mainly found in microglia but also in astroglia in the 
unilateral 6-hydroxydopamine (6-OHDA) rat model of PD. The P2X7 antagonist 3-[[5-(2,3-
dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine (A-438079) significantly reduced the 6-
OHDA-induced depletion of striatal dopamine stores. In conclusion, in addition to A2A receptors, 
other purinergic receptors, in particular the P2X7 receptor, may be involved in PD. However, 
lack of neuroprotection for the survival of dopaminergic neurons in P2X7 receptor-deficiency or 
inhibition in toxin-induced animal models of PD was reported (Hracskó et al., 2011). 
Transplanting foetal nigral grafts containing dopaminergic neurons into the brain of 
Parkinson’s patients has had limited success (Braak and Del Tredici, 2008). Transplanting 
enteric nerves (containing dopaminergic nerves) may be a promising alternative (Tew et al., 
1992). Nucleotides affect neurogenesis and have the potential to produce dopaminergic neurons 
from neural progenitor cells derived from foetal mouse midbrain (Delic and Zimmerman, 2010). 
 
3.3. Huntington's disease (HD) 
HD is an inherited motor disorder, characterized by progressive striatal neurodegeneration. The 
mutation responsible for this disease is an abnormally expanded and unstable CAG repeat within 
the coding region of the gene encoding the huntingtin protein. GABAergic enkephalin neurons of 
the basal ganglia are the most vulnerable cells in HD. They show the highest levels of expression 
of adenosine A2A receptors. This selective neuronal vulnerability occurs despite ubiquitous 
expression of mutant and normal huntingtin suggests that these receptors might play a 
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pathogenetic role in HD (Popoli et al., 2007, 2008). Changes in A2A receptor expression and 
signalling in both experimental models of HD (Tarditi et al., 2006) and in peripheral blood 
circulating cells of HD patients (Varani et al., 2001, 2007) support this hypothesis. However, the 
functional significance of the aberrant A2A receptor phenotype in HD is complicated by 
conflicting data about the potential neuroprotective and neurodegenerative effects of these 
receptors in the brain. In experimental models of HD, both A2A receptor agonists and antagonists 
have shown beneficial effects (Popoli et al., 2008). A2A receptor KO mice showed significantly 
worse motor performances and survival (Mievis et al., 2011).  
The P2X7 receptor also appears to be involved in HD. Increased P2X7 receptor levels 
and altered P2X7 mediated calcium permeability in somata and terminals of HD neurons were 
shown using transgenic mice HD models (Díaz-Hernández et al., 2009). Also, cultured neurons 
expressing mutant huntingtin exhibited increased susceptibility to apoptosis triggered by P2X7 
receptor stimulation. Administration in vivo of Brilliant Blue G (BBG), a P2X7 antagonist, to 
HD mice prevented neuronal apoptosis and attenuated body weight loss and motor-coordination 
deficits.  
 
3.4. Multiple sclerosis (MS) 
Both P2X7 and P2Y receptors have been shown to be involved in MS. Nucleotides, which are 
released in high amounts under inflammatory conditions and following cell death, may regulate 
remyelination processes in demyelinating diseases.  Different types of P2 receptors expressed by 
oligodendrocyte progenitor cells (OPs), cells that give rise to mature myelinating 
oligodendrocytes, were described (Agresti et al., 2005b). Nucleotide-induced Ca2+ raises in these 
cells are mainly due to the activation of P2X7 and P2Y1 receptors. ATP and ADP stimulated 
migration but inhibited the mitogenic response of OPs to platelet derived growth factor. 
Decreased levels of P2Y12 receptors were observed in proximity to demyelinating lesions in 
sections of cerebral cortex from post-mortem MS brains (Amadio et al., 2010). This was 
correlated with the extent of demyelination found in gray matter cortical plaques and subcortical 
white matter. 
There was a marked increase of P2X7 immunoreactivity in reactive astrocytes of autopsy 
brain tissues from MS patients (Narcisse et al., 2005). In human MS specimens, the density of 
P2X7 receptors on microglial cells was significantly increased in affected regions. P2X7 receptor 
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blockade prevented ATP excitotoxicity in oligodendrocytes, reduced demyelination and 
ameliorated neurological symptoms in experimental autoimmune encephalomyelitis (EAE), a 
model of MS (Matute et al., 2007). Moreover, development of this model was suppressed in 
P2X7 KO mice (Sharp et al., 2008). In brain homogenates of EAE rats there was increased levels 
of P2X7 receptor protein (Grygorowicz et al., 2011). In another study, patients with relapsing-
remitting MS showed strikingly reduced numbers of blood regulatory T (Treg) cells expressing 
CD39. Activated Treg cells are able to abrogate ATP-related effects, which is consistent with the 
hypothesis that there is an increase in P2X7 receptor-mediated cell cytotoxicity in MS 
(Borsellino et al., 2007). However, P2X7 receptor KO mice were shown to develop more severe 
clinical and pathological expression of EAE than WT controls (Chen & Brosnan 2006).  
GPR17, a P2Y-like receptor, was shown to be involved in repair of demyelinating 
wounds in two distinct stages of early slowly proliferating OPs that are present in the 
parenchyma of the adult brain (Lecca et al., 2008). Mature oligodendrocytes no longer expressed 
GPR17, suggesting that the receptor has to be down-regulated to allow cells to proceed to 
terminal differentiation. Activation of GPR17 by uridine 5’-diphosphate (UDP) or UDP-glucose 
caused progression of immature OPs towards mature myelinating oligodendrocytes (Ceruti et al., 
2011; Fumagalli et al, 2011). GPR17 inhibition or knockdown by siRNAs impaired the normal 
differentiation of OPs (Fumagalli et al., 2011). Lymphocytes from MS patients upregulate A2A 
receptors that mediate anti-inflammatory actions (Vincenzi et al., 2013). 
 
3.5. Amyotrophic lateral sclerosis (ALS) 
The involvement of purinergic signalling in ALS, in particular P2X4 and P2X7 receptor 
subtypes, has been proposed. The density of P2X7 microglial cells/macrophages was 
significantly increased in human ALS specimens (Yiangou et al., 2006). Up-regulation of P2X4, 
P2X7 and P2Y6 receptors and down-regulation of ATP-hydrolyzing activities was reported in 
microglia from transgenic mice over-expressing human superoxide dismutase 1 (SOD1), an 
animal model of ALS (D’Ambrosi et al., 2009). In SOD1 astrocyte cultures, repeated stimulation 
by ATP or BzATP caused astrocytes to become neurotoxic, inducing death of motor neurons and 
P2X7 receptor involvement was supported by BBG inhibition of the ATP and BzATP effects 
(Gandelman et al., 2010). Increased ATP-dependent proliferation and a basal increase in 
extracellular ATP degradation was also seen in SOD1 astrocytes. Thus purinergic activation of 
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both astrocytes and microglia in ALS may constitute a route involved in disease progression.  
High P2X4 receptor expression was shown to be selectively localised on degenerating 
motoneurons in the ventral horn of the spinal cord in a transgenic rodent model of ALS, the 
SOD1G93A (Casanovas et al., 2008). P2X4 receptors were also seen on degenerating neurons in 
the locus coeruleus, reticular formation and Purkinje cells in the cerebellum. P2X4 receptor 
antibodies cross-react with misfolded forms of mutant SOD1 that is present in neurons, but not in 
glial cells (Hernández et al., 2010). It was concluded that neuronal SOD1G93A conformers with 
P2X4 receptor immunoreactivity may have pathogenic relevance in the promotion of 
neuroinflammation. 
It has been claimed that the death of motoneurons in ALS can be reduced by adenosine 
A2A receptor antagonists (Mojsilovic-Petrovic et al., 2006). It was concluded in a review that 
purinergic signalling plays complex roles in ALS, a multifactorial and multisystemic disease 
involving participation of microglia, astrocytes, muscle and T cells, as well as neurons in 
different places (Amadio et al., 2011). 
P2X7 receptor activation increases the pro-inflammatory actions of microglia in the 
SOD1G93A mouse model of ALS and in P2X7 KO mice where there is increased gliosis and 
motoneuron death (Apolloni et al., 2013). However, spinal cord injury is reduced by P2X7 
receptor antagonists in the SOD1-mutant mouse model (Apolloni et al., 2014). A comparison 
was made of microRNAs transcriptional profiling of non-transgenic and ALS microglia in 
resting conditions and after inflammatory activation by a P2X7 receptor agonist (Parisi et al., 
2013). 
 
4. Neuroprotection 
Protection against neural damage caused by trauma, ischaemia, stroke and neurodegenerative 
diseases is the focus of many current investigations. Reviews have been published concerned 
with the roles in neuroprotection of adenosine (Stone, 2005; Chen et al., 2007; Ribeiro, 2008; 
Williams-Karnesky and Stenzel-Poore, 2009; Gomes et al., 2011) and of ATP (Skaper, 2007, 
2011; Peterson et al., 2010; Burnstock et al., 2011; Burnstock and Verkhratsky, 2012; Watts et 
al., 2013; Corps et al., 2015). In the Editorial about the Hot Topic Issue of CNS & Neurological 
Disorders-Drug Targets entitled ‘Pharmacology and Therapeutic Activity of Purinergic Drugs for 
Disorders of the Nervous System’, attention is drawn to the variety of drugs acting on P2X and 
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P2Y receptor subtypes being explored for the treatment of neurodegenerative diseases (Volonté 
and Burnstock, 2012). 
ATP, released during trauma, acts via P2 receptors to inhibit the release of the cytotoxic 
excitatory transmitter, glutamate, and stimulates release of the inhibitory transmitter, GABA, 
from hippocampal nerves, thus serving a protective role (Inoue, 1998). Excessive activation of 
glutamate receptor systems is implicated in neuronal cell death associated with stroke and 
neurodegenerative diseases such as AD, PD, HD and ALS (Zona et al., 2000). Guanine 
nucleotides inhibit N-methyl-D-aspartate (NMDA)- and kainate-induced neurotoxicity and may 
be used to antagonise glutamate receptor-mediated neurotoxicity (Morciano et al., 2004). The P1 
receptor antagonist, caffeine, is claimed to have beneficial actions in both AD and PD (Ribiero et 
al., 2003). P2 receptors have been claimed to mediate neuroprotective effects in the cerebellum, 
suggesting the use of P2 receptor agonists as neuroprotective agents (Volonté et al., 2003). It has 
been suggested that adenine is involved in the control of Purkinje cell survival (Watanabe et al., 
2003). 
 
4.1. Neuroprotection against trauma, ischaemia and stroke 
The release of adenosine is considered to be a neuroprotective factor during traumatic and 
hypoxic/ischaemic CNS injury (Nieber et al., 1999; Sebastião and Ribeiro, 2009; Stone et al., 
2009). Both neuronal morphology and behavioural tests revealed full preservation of spatial 
memory and learning ability. In vivo studies indicated a beneficial effect of A1 receptor 
stimulation in cerebral ischaemia, but the therapeutic value was limited by the wide receptor-
distribution on neuronal and non-neuronal cells in the CNS (Stone et al., 2009).  
The protective effect of A2A receptor agonists in ischaemia may be largely due to reduced 
glutamate outflow, particularly from glial cells (Popoli et al., 1995, 2003; Pedata et al., 2007). 
Decreased activation of mitogen-activated protein kinases that are involved in neuronal death 
may also contribute to neuroprotection by A2A antagonism (Kawasaki et al., 1997). A2A receptors 
trigger the actions of neurotrophic factors involved in axonal outgrowth or synaptic plasticity 
(Sebastião and Ribeiro, 2009), so blockade of A2A receptors may reduce the effects of 
neurotropic factors, favouring neuronal survival and regeneration. In neurodegenerative 
disorders astrocyte death may occur and complicate the outcome of brain ischaemia. A2A 
receptor antagonists SCH 58261 (Monopoli et al., 1998) and 8-(3-chlorostyryl)caffeine (Von 
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Lubitz et al., 1995) were protective in global or focal cerebral ischaemia in both rats and gerbils 
(Pedata et al., 2005). Also cerebral infarction was significantly attenuated in A2A receptor KO 
mice (Chen et al., 1999). A2A receptor antagonists were also beneficial for rabbit spinal cord 
reperfusion injury (Cassada et al., 2001). The A3 receptor agonist chloro-N
6-(3-iodo-benzyl)-
adenosine-5'-N-methyluronamide decreased experimentally-induced cerebral infarction in gerbils 
and rats (Chen et al., 2006; Von Lubitz et al., 1994). The protective role of A1 adenosine 
receptors in hypoxia/ischaemia in vitro in brain slice preparations was also reported (e.g. 
Fujiwara et al., 1987; Nieber et al., 1995; Krnjevic, 1999).  
Potential benefits of P2X7 receptor antagonism in rodent studies of brain and spinal cord 
injury and neurodegenerative diseases have been described (Wang et al., 2004; Bartlett et al., 
2014; Sperlágh and Illes, 2014). This has prompted the use of drugs targeting the P2X7 receptor 
for the treatment of human CNS disorders. However, these studies are facing problems, partly 
due to the many polymorphic variations of the human P2X7 receptor. Microglial cells possess 
P2X7 receptors which become activated in a rat model of focal cerebral ischaemia to participate 
in the early defence reaction (Melani et al., 2006). P2X7 receptor antagonists adenosine 5’-
triphosphate-2’,3’-dialdehyde (oxidized ATP) or BBG even 15 minutes after spinal cord injury 
resulted in recovery of hind limb motor function (Peng et al., 2009). In the cerebral cortex of 
spontaneously hypertensive rats, there was up-regulation of P2X7 receptor immunoreactivity in 
the penumbra surrounding the necrotic region (Franke et al., 2004a). In ATP-induced secondary 
damage, via stimulation of P2X (probably P2X7) receptors in the penumbra, both suramin and 
PPADS reduced the infarct volume and accelerated functional recovery in behavioural tests 
(Kharlamov et al., 2002; Lämmer et al., 2006, 2011). P2X7 receptor-activated microglia protect 
neurons against glutamate toxicity (Suzuki et al., 2004). PPADS, a P2 receptor antagonist, 
confers neuroprotection against glutamate/NMDA toxicity (Lin et al., 2005). It has been claimed 
that P2X7 receptor antagonists are neuroprotective for their ability to inhibit assembly of 
inflammasome in glial cells (Murphy et al., 2012). Cerebral ischaemia-reperfusion injury is a 
primary cause of ischaemic stroke and ischaemic postconditioning is considered as an important 
technique to contain ischaemia-reperfusion injury, which involves the activation of P2X7 
receptors (Bindra et al., 2014). Cortical spreading depression is a model of preconditioning that 
provides tolerance to a subsequent ischaemic event in the brain. It appears to be due to release of 
ATP via connexin-36 hemichannels into the extracellular space (Schock et al., 2008). The ATP, 
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via activation of P2Y receptors and new protein synthesis, causes ischaemic tolerance and 
enhances neuronal survival in cultured primary cortical neurons.  
 P2Y receptor antagonists are potential neuroprotective agents in the cortex, 
hippocampus and cerebellum by modulation of kainate- and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid-induced currents. Inhibition of apoptosis by P2Y2 receptor activation has 
been claimed to be a novel pathway for neuronal survival (Arthur et al., 2006). P2Y1 receptor 
antagonists improve recovery from traumatic brain injury (Choo et al., 2013). A recent paper 
reports that neuroprotection against genotoxic stress is elicited by P2Y13 receptor activation 
(Morente et al., 2014). The P2Y-like receptor, GPR17, is a sensor of brain damage and reacts to 
the release of nucleotides and cysteinyl leukotrienes in a focal ischaemia model (Lecca et al., 
2008). It is expressed on OPs, but not astrocytes and is a potential target for stroke and spinal 
cord injury induced by acute compression (Ceruti et al., 2009).  The in vivo knock-down of 
GPR17 by an antisense oligonucleotide strategy markedly reduced tissue damage. It has been 
claimed that P2Y2 receptors activate neuroprotective mechanisms in astrocytes (Chorna et al., 
2004). 
ATP-MgCl2 decreases lipid peroxidation in spinal cord injury and protect the spinal cord 
from secondary injury after trauma. It was concluded that ATP-MgCl2 should be explored for the 
treatment of spinal cord injuries in conjunction with other treatments (Cakir et al., 2003). After 
spinal cord injury, topical application of ATP significantly improved locomotor function (Shields 
et al., 2004). 
 
4.2. Neuroprotection against neurodegenerative diseases 
Data from animal models of AD and in samples from AD patients, support the concept that Aβ1-
42-induced synaptic dysfunction and neuronal death may involve abnormalities in purinergic 
receptor signalling, with the most convincing evidence for P2X7 receptors (see Takenouchi et 
al., 2010). Processing of APP is regulated by two different nucleotide receptors, P2X7 and P2Y2, 
with opposite effects on α-secretase activity (León-Otegui et al., 2011). It was suggested that 
activators of the P2Y2 receptor in combination with P2X7 receptor antagonists could have 
beneficial effects by reducing amyloid plaques (Wurtman et al., 2009). Block of P2X7 receptor-
mediated activity with BBG was shown to be neuroprotective in an animal model of AD (Ryu 
and McLarnon, 2008). Activation of microglia by A requires P2X7 receptor expression and it 
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was suggested that Aβ microglia stimulation may open new avenues for the treatment of AD 
(Sanz et al., 2009). ATP, released from astrocytes, protects Aβ-induced impairment of synaptic 
plasticity (Jung et al., 2012). P2X7 may also have beneficial effects via the stimulation of non-
amyloidogenic processing of APP by α-secretases, leading to proteolytic cleavage within the Aβ 
peptide sequence and shedding of the soluble APP ectodomain (sAPPα), exerting 
neuroprotection (Delarasse et al., 2011). 
 Antagonists of the A2A receptor alleviate symptoms in PD patients. Ongoing research 
programs in this area, and orally efficacious A2A receptor antagonists, have been advanced into 
clinical development (see Shah and Hodgson, 2010). Several xanthines and non-xanthine 
compounds possessing good affinity have been introduced. BIIB014, preladenant and ST-1535 
are new adenosine A2A receptor antagonists currently in use. A2A antagonists may also be 
neuroprotective under certain toxicity paradigms (see Stone et al., 2009). There are Phase I and II 
clinical trials for evaluation of their efficacy in PD patients (Pinna, 2009). All these compounds 
were safe and well tolerated. Results from the Phase II trial showed that BIIB014 and 
preladenant were effective in reducing the waking time spent in OFF state in patients at the late 
stage of PD treated with L-DOPA. BIIB014 was also effective as monotherapy in patients at the 
early stage of PD and ST-1535 displays a promising potential in experimental models of PD and 
in clinical studies. The therapeutic effects of A2A receptor antagonists appear to act via a 
reduction of the inhibitory output of the basal ganglia indirect pathway. This possibility has been 
validated in patients treated with the A2A antagonist SYN115 (Black et al., 2010). 
Neuroprotective mechanisms also include blockade of A2A receptor-mediated glutamate release 
from neurons, inhibition of microglia-induced inflammation. However, there is conflicting data 
on the protective and detrimental roles reported for A2A receptors in the CNS. Diadenosine 
tetraphosphate (AP4A), an endogenous diadenosine polyphosphate, also has protective effects in 
the unilateral 6-OHDA rodent model of PD (Wang et al., 2003). AP4A also reduced TUNEL in 
the lesioned nigra 2 days after 6-OHDA administration, implying inhibition of apoptosis.  
Therapeutic potential of P2X7 receptor antagonists for the treatment of HD was discussed 
(Díaz-Hernández et al., 2009). Decrease in stimulated A1 and A2A receptors has also been 
implicated in HD (Bauer et al., 2005; Popoli et al., 2007). Alterations of P2X7 receptor activity 
could contribute to HD pathogenesis and highlight the therapeutic potential of P2X7 receptor 
antagonists. A2A receptor agonists protect neurons derived from induced pluripotent stem cells of 
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patients with HD (Chern et al., 2014). The level of 5’-nucleotidase increased in synaptosomes 
from the cerebral cortex of rats that were experimentally demyelinated (Spanevello et al., 2006).  
An early feature of MS and its animal model of EAE is neuronal pathology. Lesional 
accumulation of P2X receptors on macrophages in rat CNS in the EAE model has been reported 
(Guo and Schluesener, 2005). P2X7 expression is elevated in axon tracts in patients with MS and 
ATP can kill oligodendrocytes by activating P2X7 receptors (Domercq et al., 2010). Patients 
exhibiting the remitting/relapsing form of MS have strikingly reduced numbers of NTPDase1-
positive Treg cells, suggesting that purines might be involved (Borsellino et al., 2007). A 
regulatory role of P2Y1 receptor signalling in OPs has been described (Agresti et al., 2005a). It 
was suggested that high ATP released in inflammatory conditions might act on P2Y1 receptors to 
influence the remyelination processes in MS. In the lesioned cerebral cortex of MS patients 
P2Y12 receptor expression has also been identified (Amadio et al., 2010). GPR17 is a key 
regulator of OP differentiation. GPR17 dysfunctions seem be present in MS, setting the 
background for future GPR17-based remyelination therapies (Chen et al., 2009).  
The protective effect mediated by both ATP and ivermectin for ALS is by potentiation of 
ATP action on P2X4 receptors (Andries et al, 2007). Preincubation of motor neurons with a low 
concentration of ATP protected cells against excitotoxic stimulation, while high concentrations 
of ATP were toxic. To study the relevance of these findings for ALS, SOD1G93A-mice were 
treated with ivermectin. This led to an increase of the life span of these mice by almost 10%. The 
increased expression of P2X1 receptors on axotomized facial motoneurons was impaired in 
SOD1G93A-mutant mice (Kassa et al., 2007). It was suggested that the release of ATP from 
mutant motor neurons is altered after damage.  
 
5. Neuroregeneration: neural stem/progenitor cells 
A major obstacle for neural repair is the weak regenerative capacity of injured neurons, although 
the neonatal brain has a greater capacity for recovery than the adult brain (Pekovic et al., 2006). 
There are a number of reports about the role of purinergic drugs promoting regeneration of 
injured and degenerating nerves in the brain and spinal cord. Both A1 and A2 receptors mediate 
proliferation of microglia (Gebicke-Haerter et al., 1996). Inosine has been shown to stimulate 
axonal growth in the rat corticospinal tract after injury (Benowitz et al., 1999, 2001). PKB/Akt is 
a signalling molecule that regulates cell survival, growth and metabolism and inhibits apoptosis. 
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Traumatic brain injury activates Akt. ATP is released when cortical astrocytes were subjected to 
mechanical strain, leading to Akt activation and PPADS attenuated the Akt activation (Neary et 
al., 2005). Mechanical strains, comparable to those that occur in humans exposed to traumatic 
brain injury, cause release of ATP from astrocytes. Then there is activation of purinergic 
receptors coupled to protein kinase cascades that regulate expression of genes involved in long-
term, trophic actions (Neary et al., 2006). Activation of purinergic signalling in astrocytes via 
P2Y4 receptors induced by trauma stimulates the synthesis and release of thrombospondin-1, an 
extracellular matrix molecule that induces synapse formation during development and may play 
a role in CNS repair and remodelling after injury (Tran and Neary, 2006).  
ATP and its analogues are involved in tissue remodelling in response to injury and have a 
key role in regulation of repair and regeneration (Burnstock and Verkhratsky, 2010). Stimulation 
of purinoceptors in the CNS triggers astrogliosis, the response of astrocytes to brain damage, 
which is characterised by cell proliferation and remodelling of the neural circuitry (Giaume et al., 
2007). In combination with growth factors such as fibroblast growth factor, epidermal growth 
factor and platelet-derived growth factor, ATP can stimulate astrocyte proliferation, contributing 
to the process of reactive astrogliosis (Abbracchio and Burnstock, 1998; Ishibashi et al., 2006; 
Neary et al., 2006). P2Y receptors are claimed to mediate reactive astrogliosis via induction of 
cyclo-oxygenase-2, and P2Y receptor antagonists reduce astrogliosis (Brambilla et al., 1999). 
Reactive astrogliosis is instrumental for limitation of brain damaged area, as well as for the post-
insult remodelling and recovery of neural function. Initial events in astroglial responses to 
purinergic signalling appear to be associated with P2Y1 and P2Y2 receptor-mediated Ca
2+ 
astroglial signalling (Kirischuk et al., 1995). It has been claimed that activation of P2Y2 
receptors can promote regeneration of nerves and glial cells in damaged brain (see Arthur et al., 
2005; Franke, 2011). Intraneural injection of Aβ has been shown to stimulate regeneration of 
primary sensory axons in the spinal cord (Wu et al., personal communication). The P2Y-like 
GPR17 has been identified as a sensor of damage of the CNS and participates in lesion repair in 
the rodent brain and in patients with traumatic brain injury (Franke et al., 2013).  
Synergistic actions of ATP and growth factors were recognised in 1989 (Huang et al., 
1989). Sprouting of central neurons was shown in experiments in which the enteric nervous 
system was transplanted into the striatum of the brain (Tew et al. 1992). It was suggested that a 
growth factor released from enteric glial cells acts synergistically with ATP (and its breakdown 
22 
 
product, adenosine) and NO (Höpker et al. 1996). A similar synergistic activity of purines and 
growth factors may be involved in stem cell activity (Burnstock and Ulrich, 2011). Purines and 
pyrimidines released from damaged cells stimulate astrocyte proliferation in vitro and may 
contribute to astrocyte proliferation in vivo following injury to the CNS (Christjanson et al., 
1993). Co-operation of guanosine 5' triphosphate and nerve growth factor in neural 
differentiation and neurite outgrowth has also been described (Gysbers et al., 2000; Guarnieri et 
al., 2004). 
Neural stem (progenitor) cells are heavily involved in the development of the CNS and 
adult neural progenitor cells are also involved in regeneration following injury (Shih et al., 2001; 
Zimmermann, 2006; Lin et al., 2007; Trujillo et al., 2009; Ulrich et al., 2012). It has been 
reported that stem cell activation and the integration of newly formed neurons can be applied for 
neuroregeneration in the diseased brain (Martino and Pluchino, 2006; Omerod et al., 2008; Delic 
and Zimmermann, 2010). Neural pluripotent precursor cells derived from primary neural stem 
cells proliferate to form the three main cell types constituting the neurons, astrocytes and 
oligodendrocytes, while microglia are derived from immune-like cells. ATP causes proliferation 
of human neural stem cells (Ryu et al., 2003). Adult neural progenitor cells in the mouse 
subventricular zone express interacting functional P2X4 and P2X7 receptors (Messemer et al., 
2013a, b) and it has been proposed that P2X2 and P2X7 receptor agonists and antagonists may 
provide novel tools for regeneration therapy in neurodegenerative diseases (Glaser et al., 2013). 
In adult brains, neural stem cells are present in the subventricular zone of the lateral ventricle and 
the subgranular zone of the hippocampal dentate gyrus, where neurogenesis continues 
throughout life. Purinergic signalling promotes proliferation of rapidly dividing stem cells in the 
subventricular region via P2Y1 receptors (see Suyama et al., 2012). ATP was shown to promote 
locomotor recovery after spinal cord injury (Sun et al., 2013).  
 
6. Conclusions 
The P2X7 receptor subtype appears to be the dominant receptor involved in CNS disorders, 
which is upregulated after trauma and ischaemia and in inflammatory conditions. P1 and P2Y1 
receptors also participate in neuroprotective mechanisms. P2X7 receptor antagonists are being 
explored for the treatment of neurodegenerative diseases, including AD, HD, MS and ALS. A2A 
receptor antagonists are promising for the treatment of PD (see Table 1).  
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For major advances to be made in our knowledge of the roles of purinergic signalling in 
neurodegeneration and neuroregeneration there is an urgent need for novel compounds to be 
developed, including purinoceptor subtype agonists and antagonists and inhibitors of 
ectonucleotidases and ATP transport, that are orally bioavailable, stable in vivo and can cross the 
blood brain barrier. There are questions to be raised about the viability of some of the animal 
models currently available to replicate human CNS diseases.  
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Table 1 
Pathology Main P1/P2 receptor subtypes involved 
Trauma: injury, stroke, ischaemia A2A, P2X7, P2Y1, P2Y2  
Alzheimer’s Disease A1, A2A, P2X7, P2Y1  
Parkinson’s Disease A2A  
Huntington’s Disease A2A, P2X7  
Multiple Sclerosis P2X7, P2Y1, GPR17 
Amyotrophic Lateral Sclerosis A2A, P2X4, P2X7  
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Figure Legends 
Figure 1 
Resolution of inflammation and tissue repair. Clearing of dead cells and suppression of 
inflammation are key events in brain repair. Find-me signals (UTP, ATP) attract microglia and 
macrophages through P2Y2 receptors. Eat-me signals include UDP, which acts on P2Y6 
receptors to stimulate microglial phagocytosis, and phosphatidylserine (PtdSer), which is 
translocated to the outer leaflet of the plasma membrane of apoptotic cells. PtdSer-binding 
proteins involved in the clearance of dead cells include milk fat globule epidermal growth factor 
8 protein on microglia and T cell immunoglobulin and mucin domain-containing molecule 4 
(TIM4) on macrophages. Immunoglobulins directed against CNS antigens, which appear after 
stroke, may also promote phagocytosis by engaging Fc receptors on phagocytic cells. 
Phagocytosis promotes secretion of IL-10 and TGF-β, which, in turn, suppress antigen 
presentation, promote Treg formation, inhibit expression of adhesion molecules in endothelial 
cells and production of proinflammatory cytokines. TGF-β and IL-10 are also neuroprotective 
and may facilitate brain repair processes. In addition, lipoxins, resolvins and protectins, 
metabolites of arachidonic acid and omega-3 fatty acids that play an active part in the resolution 
of inflammation in other organs, could also contribute to suppress postischemic inflammation. 
Growth factors and MMPs produced by endothelial cells, neurons, astrocytes, oligodendrocytes 
and microglia are key molecules driving tissue reorganization and repair. (Reproduced from 
Iadecola and Anrather, 2011, with permission from The Nature Publishing Group.) 
 
